GSK Is ‘Betting Big’ on the US, CEO Walmsley Says
PositiveFinancial Markets

GSK is making significant investments in the US market, as highlighted by CEO Emma Walmsley during a recent event. She noted that the company is having productive discussions with the Trump administration regarding drug pricing, viewing Pfizer's recent pricing agreement as a positive development. This proactive approach not only positions GSK favorably in a competitive landscape but also reflects a broader trend of pharmaceutical companies engaging with government policies, which could lead to more favorable conditions for innovation and access to medications.
— Curated by the World Pulse Now AI Editorial System